Date | Price Target | Rating | Analyst |
---|---|---|---|
2/1/2024 | $30.00 | Sector Outperform | Scotiabank |
9/25/2023 | $25.00 → $32.00 | Hold → Buy | Canaccord Genuity |
8/8/2023 | $30.00 | Market Perform → Outperform | SVB Securities |
5/23/2023 | $13.00 → $27.00 | Neutral → Buy | Goldman |
8/15/2022 | $40.00 → $12.00 | Buy → Hold | Canaccord Genuity |
8/9/2022 | $38.00 → $18.00 | Outperform → Market Perform | Cowen |
8/9/2022 | $35.00 → $15.00 | Outperform → Mkt Perform | SVB Leerink |
3/2/2022 | $85.00 → $60.00 | Overweight | JP Morgan |
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue and Chief Financial Officer Vandana Sriram will take part in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 at 1:50 p.m. ET. The presentation will be available virtually and participants can register here. The presentation will be available for viewing following the conference on Quanterix's website here: ir.quanterix.com. To learn more about Quanterix, visit www.quanterix.com/company/. To learn more about Quanterix's Simoa® technology, visit: www.quanterix.com
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors. Mr. Elliott brings two decades of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp., where he served as chief financial officer from November 2016 to May 2024 and chief operating officer from April 2021 to May 2023. While at Exact Sciences, he was responsible for finance, strategy and business development, helping to effectively scale the business, achieving high revenue growth during his tenure, and overseei
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2024. "Our research business once again delivered strong performance in the second quarter, growing double digits," said Masoud Toloue, Chief Executive Officer of Quanterix. "Demand for Simoa sensitivity continues, as highlighted by a 35% increase in Accelerator service revenue compared to the corresponding prior year period, as customers are able to access our technology without impacting their capital expenditure budgets. For the balance of 2024, we expect to continue to execute against our strate
Goldman Sachs analyst Matthew Sykes maintains Quanterix (NASDAQ:QTRX) with a Buy and lowers the price target from $35 to $24.
Quanterix (NASDAQ:QTRX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.33) by 21.21 percent. This is a 62.5 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $32.066 million which beat the analyst consensus estimate of $31.620 million by 1.41 percent. This is a 12.69 percent increase over sales of $28.456 million the same period last year.
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors. Mr. Elliott brings two decades of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp., where he served as chief financial officer from November 2016 to May 2024 and chief operating officer from April 2021 to May 2023. While at Exact Sciences, he was responsible for finance, strategy and business development, helping to effectively scale the business, achieving high revenue growth during his tenure, and overseei
CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that it has appointed Vandana Sriram, CPA, as Chief Financial Officer (CFO), effective August 21, 2023. Sriram replaces Michael Doyle, who has served as the Company's CFO since July 2021. As previously announced, Mike will transition to the role of Executive Director, Finance, focusing on strategic growth programs until his retirement in March 2024. "Vandana is experienced in developing and executing strategic roadmaps and financial plans to foster growth opportunities," said Masoud Toloue, CEO at Quanterix. "The executive tea
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2024. "Our research business once again delivered strong performance in the second quarter, growing double digits," said Masoud Toloue, Chief Executive Officer of Quanterix. "Demand for Simoa sensitivity continues, as highlighted by a 35% increase in Accelerator service revenue compared to the corresponding prior year period, as customers are able to access our technology without impacting their capital expenditure budgets. For the balance of 2024, we expect to continue to execute against our strate
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Thursday, August 8, 2024 at 4:30 p.m. E.T., to discuss its second quarter 2024 financial results. Quanterix will issue a press release regarding the second quarter 2024 earnings prior to the conference call on Thursday, August 8, 2024 after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To pre-register for the conference call with a webcast link click here and for an audio only link click here to obtain your dial-in number and passcode. Interested investo
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2024. "Building on the foundation our team developed last year, Quanterix is entering a new innovation and product delivery phase," said Masoud Toloue, Chief Executive Officer of Quanterix. "We've announced the first of several new assays that could re-define the way Tau is measured from the brain versus peripheral sources. We will continue to lead in bringing novel biomarker detection solutions to market for the research community; developing tests to study and enable the early detection of neuro-pa
Scotiabank initiated coverage of Quanterix with a rating of Sector Outperform and set a new price target of $30.00
Canaccord Genuity upgraded Quanterix from Hold to Buy and set a new price target of $32.00 from $25.00 previously
SVB Securities upgraded Quanterix from Market Perform to Outperform and set a new price target of $30.00
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
SC 13G - Quanterix Corp (0001503274) (Subject)
SC 13G/A - Quanterix Corp (0001503274) (Subject)
SC 13G/A - Quanterix Corp (0001503274) (Subject)
8-K - Quanterix Corp (0001503274) (Filer)
10-Q - Quanterix Corp (0001503274) (Filer)
8-K - Quanterix Corp (0001503274) (Filer)